Loss of AMPK exacerbates experimental autoimmune encephalomyelitis disease severity. - Wikidata - awgldk - TriplyDB

Loss of AMPK exacerbates experimental autoimmune encephalomyelitis disease severity.

Loss of AMPK exacerbates experimental autoimmune encephalomyelitis disease severity.

http://www.wikidata.org/entity/Q34291918

about

Metabolic regulation of T cell differentiation and function AMPK activation--protean potential for boosting healthspan.Putative Role of AMPK in Fetal Adaptive Brain Shut-Down: Linking Metabolism and Inflammation in the Brain.AMPK inhibition in health and disease.Metabolic reprograming of mononuclear phagocytes in progressive multiple sclerosis.Loss of AMP-activated protein kinase induces mitochondrial dysfunction and proinflammatory response in unstimulated Abcd1-knockout mice mixed glial cells.Untargeted Plasma Metabolomics Identifies Endogenous Metabolite with Drug-like Properties in Chronic Animal Model of Multiple Sclerosis AMP-activated protein kinase α1 protects against diet-induced insulin resistance and obesity.Attenuation of AMPK signaling by ROQUIN promotes T follicular helper cell formation.Metabolic control of the Treg/Th17 axis AMP-activated protein kinase signaling protects oligodendrocytes that restore central nervous system functions in an experimental autoimmune encephalomyelitis model.AMP-activated protein kinase restricts IFN-γ signaling.Administration of S-nitrosoglutathione after traumatic brain injury protects the neurovascular unit and reduces secondary injury in a rat model of controlled cortical impact.AMPKα Is Suppressed in Bladder Cancer through Macrophage-Mediated Mechanisms.Rescue of mutant rhodopsin traffic by metformin-induced AMPK activation accelerates photoreceptor degeneration.Autophagy and inflammatory diseases.Metabolism of inflammation limited by AMPK and pseudo-starvation.Function of the master energy regulator adenosine monophosphate-activated protein kinase in stroke.The AMPK enzyme-complex: from the regulation of cellular energy homeostasis to a possible new molecular target in the management of chronic inflammatory disorders.ROQUIN signalling pathways in innate and adaptive immunity.AMP-Activated Protein Kinase Suppresses Autoimmune Central Nervous System Disease by Regulating M1-Type Macrophage-Th17 Axis.Metabolism in Immune Cell Differentiation and Function.5-Aminoimidazole-4-carboxamide ribonucleoside-mediated adenosine monophosphate-activated protein kinase activation induces protective innate responses in bacterial endophthalmitis.May diet and dietary supplements improve the wellness of multiple sclerosis patients? A molecular approach.A Systems Medicine Approach Reveals Disordered Immune System and Lipid Metabolism in Multiple Sclerosis Patients.The regulation effect of AMPK in immune related diseases.Combination therapy of lovastatin and AMPK activator improves mitochondrial and peroxisomal functions and clinical disease in EAE model.Metformin-induced mitochondrial function and ABCD2 up-regulation in X-linked adrenoleukodystrophy involves AMP-activated protein kinase.Anti-neuroinflammatory effect of a novel caffeamide derivative, KS370G, in microglial cells.Targeted Stage-Specific Inflammatory microRNA Profiling in Urine During Disease Progression in Experimental Autoimmune Encephalomyelitis: Markers of Disease Progression and Drug Response.The peroxisome: an update on mysteries 2.0

P2860

Q26798088-1E572EDF-F26B-4CE3-9826-5434C1282154 Q33689169-27271D47-8E40-43A7-B14B-0983F0BE20BA Q34023478-3731947B-A9E1-4593-A1AF-7CEDBEBB79D8 Q35094436-BD5D8A7D-FD0A-4415-BC98-06504F8005A5 Q35167056-E3A139FA-4312-471E-BF24-01DC7DD17991 Q35227024-BD7F4037-7A40-46F3-8EBB-9B56F848DDCD Q36407218-06615C8E-6879-48E4-8566-51991C62133F Q36410716-8FFB34D2-F690-474D-A406-9ABC3464E0B3 Q36473888-944E40C8-9D95-4BD3-A0F1-A9547ECDA230 Q36622931-DDDD7CB4-A040-4F87-B8B6-C8C5782164F0 Q37062840-20141F64-A284-4203-B5E4-6DD4AA5A1D50 Q37075106-FE9E933C-AB48-48D7-8629-CE8B17B454E9 Q37420533-83E5DDAB-20CF-4BF9-9106-850C0CDA0CE9 Q37482647-03364968-CEEE-4ECB-ADA0-1ED36A454433 Q37701985-90A52846-4BB7-47D1-81A4-2A8785584B8F Q38074032-673B957A-27A8-4A79-A480-2B8FDA6D6BBF Q38074586-1A7CF6E4-D692-49F2-B53E-4B27BECAD782 Q38086798-8C6D243B-02AB-4EE1-B2D3-DF68EDEC544F Q38594411-C150D54B-D977-4D0C-9322-B2C688AE8BB4 Q38802693-71A8E4C2-0FF7-45DB-A2FF-09D394BE96A1 Q39647288-FBD499A1-C673-4D63-AD4C-CD8BE93717B2 Q40065267-07A0F4DA-4C46-4240-AF09-DD206636B191 Q40644641-AC83DDE0-DDC6-464B-87BF-DF64089DAE6F Q42704925-F02BBE62-4328-465F-9F1B-69FA8E24C3D4 Q47342256-45659F92-C090-4E7E-94B6-582779300EB8 Q47414308-40D32024-32BB-4748-91A9-0D4A23688D3C Q47656532-E795E9D4-1EC4-4973-968E-DEFB38DAA14E Q48925414-96651686-C6DD-40FF-9C4E-E95E0E33B73A Q50878132-D3871D04-6E82-44AB-941C-E59F30AD3C68 Q53383288-3904A637-A4E1-4976-90D4-F12DC5B869C0 Q57921401-63A68FB5-54A1-4EBB-A44C-6C08B244B7A6

P2860

Loss of AMPK exacerbates experimental autoimmune encephalomyelitis disease severity.

http://www.wikidata.org/entity/Q34291918

description

2009 nî lūn-bûn

@nan

2009 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Loss of AMPK exacerbates experimental autoimmune encephalomyelitis disease severity.

@ast

Loss of AMPK exacerbates experimental autoimmune encephalomyelitis disease severity.

@en

Loss of AMPK exacerbates experimental autoimmune encephalomyelitis disease severity.

@nl

type

label

Loss of AMPK exacerbates experimental autoimmune encephalomyelitis disease severity.

@ast

Loss of AMPK exacerbates experimental autoimmune encephalomyelitis disease severity.

@en

Loss of AMPK exacerbates experimental autoimmune encephalomyelitis disease severity.

@nl

prefLabel

Loss of AMPK exacerbates experimental autoimmune encephalomyelitis disease severity.

@ast

Loss of AMPK exacerbates experimental autoimmune encephalomyelitis disease severity.

@en

Loss of AMPK exacerbates experimental autoimmune encephalomyelitis disease severity.

@nl

P1433

Q34291918-E30DFB5D-71FA-4DCD-9888-8D8F6430CAB5

P1476

Q34291918-83995C8D-AA76-4DD5-88A3-B003691F08FA

P2093

Q34291918-03958C9A-218A-43F4-8999-ACF2FC845199

Q34291918-4530C1D7-E9B0-4017-9A65-8EBAEA95F2B9

Q34291918-4E0818A5-407D-46EA-BF1D-F7372FA0319C

Q34291918-4F357E19-178C-48FA-8DD8-1C2E55F806E6

Q34291918-60D94722-AAB9-45A4-BF8A-0BE5DF181E11

Q34291918-6A57F6C3-9C81-4E60-BC0D-2428D53354EA

Q34291918-97433522-E9B7-461B-B186-C63D95CE6254

Q34291918-C2A6E9F8-F486-4F52-ACFC-554C24AA1C99

P2860

Q34291918-0AF561ED-0CCB-4AE9-A8B7-621204D1EAE9

Q34291918-203B600C-F69E-4AC7-A9B9-03781788AE0B

Q34291918-227E1E8B-0AD5-495A-929F-F31C728432AF

Q34291918-29E39378-55EC-4319-9A67-97F058EA1E14

Q34291918-33318A77-E22F-4007-95F5-50C228950549

Q34291918-47D06BCD-0C6C-4513-90E4-02E0237476DC

Q34291918-4BEAD6DE-4DA3-41D3-898A-D59B0F447C71

Q34291918-7D50BCE2-18E7-426D-B03F-409D0F8ED1E7

Q34291918-80389EC1-29D4-4036-8F1D-C48DA2BA4A34

Q34291918-99BE7758-139A-4F76-861B-AA04DFDED641

P304

Q34291918-9E0D9659-EC9E-4BEB-AE04-EEA7855F048A

P31

Q34291918-D5C7F38F-1E16-47DE-AA73-F8B388EEC7A9

P356

Q34291918-9E98227A-A3B8-42A8-99C0-220A0541E193

P407

Q34291918-53AB8A7F-93AE-4867-A0B7-60AEDDDB117A

P433

Q34291918-6FDF5925-6E01-40BD-B037-8ECE0CB9CDBF

P478

Q34291918-1CABFAB2-ADB9-4BCE-A1AB-2FB4AAAA4489

P50

Q34291918-7E1EAC07-D2A0-4BB6-8D8B-7F7A304E1DD3

Q34291918-E64DE7FF-5FCC-4E15-A858-706FEA68E2CF

Q34291918-E7386F61-2E14-4488-8376-E9321A31E5C8

P577

Q34291918-80B476F2-6D8A-4CED-ABC5-C24370678ED1

P5875

Q34291918-2CF23596-A69D-4FCC-9221-72218CEAA6DE

P698

Q34291918-0835AF10-7DDF-4010-B100-A12F10461862

P921

Q34291918-9E153744-7CB6-4797-99BD-D4D713348EAC

P932

Q34291918-E9EE0CEA-FE5C-4895-A4BD-6BDE5D3AF4FD

P356

J.BBRC.2009.05.106

P1433

Biochemical and Biophysical Research Communications

P1476

Loss of AMPK exacerbates experimental autoimmune encephalomyelitis disease severity.

@en

P2093

Carloe de Meester

http://www.w3.org/2001/XMLSchema#string

Inderjit Singh

http://www.w3.org/2001/XMLSchema#string

Luc Bertrand

http://www.w3.org/2001/XMLSchema#string

Musfiquidin Khan

http://www.w3.org/2001/XMLSchema#string

Narender Nath

http://www.w3.org/2001/XMLSchema#string

Ramandeep Rattan

http://www.w3.org/2001/XMLSchema#string

Randhir S Makkar

http://www.w3.org/2001/XMLSchema#string

Shailendra Giri

http://www.w3.org/2001/XMLSchema#string

P2860

Downregulation of AMP-activated protein kinase by Cidea-mediated ubiquitination and degradation in brown adipose tissue

The AMP-activated protein kinase alpha2 catalytic subunit controls whole-body insulin sensitivity

Activation of yeast Snf1 and mammalian AMP-activated protein kinase by upstream kinases.

Control of AMPK-related kinases by USP9X and atypical Lys(29)/Lys(33)-linked polyubiquitin chains

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

Mammalian TAK1 activates Snf1 protein kinase in yeast and phosphorylates AMP-activated protein kinase in vitro.

Management of cellular energy by the AMP-activated protein kinase system.

Metformin attenuated the autoimmune disease of the central nervous system in animal models of multiple sclerosis

Interferons in relapsing remitting multiple sclerosis: a systematic review.

Lack of evidence for use of glatiramer acetate in multiple sclerosis.

P304

16-20

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BBRC.2009.05.106

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

386

http://www.w3.org/2001/XMLSchema#string

P50

Ashutosh Mangalam

P577

2009-05-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26257676

http://www.w3.org/2001/XMLSchema#string

P698

19486896

http://www.w3.org/2001/XMLSchema#string

P921

experimental autoimmune encephalomyelitis

P932

2976596

http://www.w3.org/2001/XMLSchema#string